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Abstract
Eden, Christopher James. Ph.D. in Biology. The University of Memphis. 2014. Orthotopic
models of pediatric brain tumors in zebrafish. Major Professor: Richard Gilbertson.

High-throughput screens (HTS) of compound toxicity against cancer cells in vitro can
identify thousands of potential new drug-leads.

But only limited numbers of these lead

compounds can progress to expensive and labor intensive in vivo efficacy studies in mice,
creating a ‘bottle-neck’ in the drug development pipeline. Experimental systems to triage HTS
leads for further study are greatly needed. Here, we adapted a series of accurate mouse models
of pediatric brain tumors to grow as orthotopic implants in the brains of zebrafish. Freshly
isolated mouse ependymoma, glioma and choroid plexus carcinoma cells expressing red
fluorescence protein (RFP) were acclimatized to grow at 28oC.

Tumor cells were then

transplanted orthotopically into the brains of zebrafish. Live in vivo fluorescence imaging
identified robust, quantifiable and reproducible brain tumor growth as well as spinal metastasis
in zebrafish. Tumor xenografts also retained the histological and transcriptomic characteristics
of the corresponding mouse parent tumor and efficiently recruited fish endothelial cells to form
a typical tumor vasculature. Finally, by treating zebrafish harboring ERBB2-driven gliomas
with an appropriate cytotoxic chemotherapy (5-fluorouracil) or tyrosine kinase inhibitor
(Erlotinib), we show that these model systems can effectively test drug efficacy and
pharmacodynamic activity. Our data demonstrate, for the first time, that mouse models of
brain tumors can be orthtopically transplanted into fish and serve as a platform to study drug
efficacy. Since large cohorts of brain tumor bearing zebrafish can be generated rapidly and
inexpensively, these models may serve as a powerful tool to triage HTS ‘hits’ for formal
efficacy testing in mice.
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Chapter 1
Introduction
Brain tumors include the most lethal forms of childhood cancer, but few new
treatments of these diseases have been developed during the last 30 years (M. A. Smith et
al., 2010) . This therapeutic impasse has resulted in part from a paucity of disease
models that are amenable to high-throughput screens (HTS) and preclinical efficacy
testing of new drugs. Recently, our group and others have developed accurate mouse
models of pediatric medulloblastoma, glioma, ependymoma and choroid plexus
carcinoma that together represent >60% of all childhood brain tumors (Chow et al., 2011;
Gibson et al., 2010; Johnson et al., 2010; Kawauchi et al., 2012; Pei et al., 2012). Since
these models recapitulate the various subtypes of pediatric brain tumors (M. A. Smith et
al., 2010) that are likely to require different treatments, they have great potential to
discover new therapies for all patients. The development of the Smoothened inhibitor
Vismodegib for the treatment of Sonic hedgehog (SHH)-subtype medulloblastoma using
the Ptch+/-;Tp53-/- mouse model, provides proof-of-principle of this approach (Robarge et
al., 2009; Romer et al., 2004). In addition to developing targeted therapies, we have
shown that mouse brain tumor models can be used in HTS campaigns: identifying bolus
5-fluorouracil as a new treatment of ependymoma that has now entered clinical trial
(Atkinson et al., 2011).
The integration of cell culture and robotic technologies has made HTS a powerful
drug discovery tool, identifying hundreds of lead compounds with potent anticancer cell
activity (Szymanski, Markowicz, & Mikiciuk-Olasik, 2012), but further triaging of these
compounds for expensive and time consuming in vivo pharmacokinetic and efficacy
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testing in mice can be difficult. We reasoned that zebrafish might provide a relatively
inexpensive and high-throughput system to triage compounds between cell-based HTS
and definitive mouse model studies. Although the zebrafish flank, abdomen and brain
can serve as efficient host tissues for human melanoma, this species has not been studied
as a host for brain tumor or mouse cancer xenografts (Lee, Seftor, Bonde, Cornell, &
Hendrix, 2005).
Here we report an efficient system that allows mouse brain tumors to be grown in the
brains of zebrafish. These tumors recapitulate the histology and transcriptome of the
parent mouse tumor and can be used to test drug efficacy. Since large cohorts of
zebrafish bearing brain tumors can be generated rapidly and inexpensively, these models
may serve as a powerful new tool in the drug development pipeline between cell-based
HTS and formal efficacy testing in mice.
Literature Review
Pediatric Brain Tumors are the Leading Cause of Solid Tumor Related Death in
Children
Brain tumors represent the most common childhood solid malignancy and are the
leading cause of cancer related death in children (Table 1). Despite advances in
diagnostics and treatment, pediatric brain tumors remain the second most common cause
of childhood cancer mortality (Murphy, 2013). Although there have been advances in
treatment resulting in increased survivorship in most pediatric cancers, very few
advances have been made regarding the treatment of pediatric brain tumors (Schroeder,
Hoeman, & Becher, 2014). This is mainly due to the fact that few genetic alterations
have been identified that segregate neoplastic cells, and the few targets that are identified
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lack corresponding drugs that target them (Schroeder, 2014). Also, often the
chemotherapeutics used for pediatric cancer are based on the efficacy of these drugs on
adult tumors (DeVita & Chu, 2008). However, new technological advances, largely in
genomics, have shown that pediatric tumors are molecularly distinct from adult tumors
(Deffenbacher et al., 2012; Paugh et al., 2010; Schroeder, Hoeman & Becher, 2014;
Sturm et al., 2014). Therefore, it is likely that pediatric and adult cancers will require
different forms of treatment. Ependymoma, glioma, and choroid plexus carcinoma
represent three devastating types of childhood brain tumors. A better understanding of
these diseases is needed in order to identify potential treatments (Johnson et al., 2010;
Ruland et al., 2014; Singh et al., 2003; Smith et al., 2014)

Table 1
Estimated Cases for Childhood and Adolescent Cancers,
US 2014 (2014 American Cancer Society)
Site
Acute lymphocytic leukemia
Brain and CNS
Neuroblastoma
Non-Hodgkin lymphoma
Acute myeloid leukemia
Bone tumors
Hodgkin lymphoma
Rhabdomyosarcoma
Retinoblastoma
All sites

Children (ages 0-14)
2,670 (26%)
2240 (21%)
710(7%)
620 (6%)
500 (5%)
450(4%)
380(4%)
340(3%)
280(3%)
113,782
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Ependymoma
Incidence and pathology. Ependymomas are one of four types of ependymal tumor
that originate throughout the CNS from the wall of the ventricular system and the spinal
canal (Kleihues et al., 2002). These World Health Organization grade II tumors
ultrastructural properties of ependymal cells, display moderate cellularity, and express
glial differentiation markers (Kleihues et al., 2002). Ependymomas originate in posterior
fossa (PF), supratentorial (ST) or spinal cord (SC) compartments (Raghunathan et al.,
2013). Ependymomas arise in all age groups, but children and adults develop these
tumors in different areas of the CNS (Moynihan, 2003). For example, 90% of all
pediatric ependymoma tumors are intracranial while spinal tumors are more commonly
found in in adult patients (Andreiuolo et al., 2010). Confounding factors such as the
heterogeneity of histology, clinical presentation of ependymoma, and the separation of
pediatric and adult oncology services, have hindered efforts to coordinate clinical trials in
this disease (M. E. a. G. R. Merchant, 2010). As a result, no new therapeutic approaches
have been identified to treat ependymoma during last 20 years resulting in 40% of
patients remaining incurable (Brandes et al., 2005; Merchant & Fouladi, 2005).
Molecular biology. Historically, cancer treatment has been based solely on tumor
histology collected from patient biopsies (Taylor et al., 2005). However, despite similar
tumor phenotype, there is a major discrepancy in patient response to treatment (Mack &
Taylor, 2009). This differential response to treatment for a particular cancer might be
due to the underlying genetic heterogeneity of the tumor (Mack & Taylor, 2009). Recent
advancements in genomics have allowed researchers to map the complete genome of
several cancers revealing the once thought to be homogeneous diseases are in fact
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molecularly distinct subgroups (Gibson et al., 2010; Johnson et al., 2010a; Nutt et al.,
2003). To better understand the biological heterogeneity that has been documented in
ependymoma (Taylor et al., 2005), Johnson et al. (2010) conducted a genomic analysis of
204 patient samples identifying DNA copy number alterations and RNA expression
profiles. These results separated ependymoma into 9 distinct subgroups (Figure 1). This
was done by using the AGDEX (Agreement of Differential Expression)

Figure 1. Ependymomas from different parts of the CNS are molecularly distinct
diseases. Comparison of ependymoma subgroups identified by hierarchial cluster
analysis of mRNA (top, n=83) and miRNA (bottom n=64) tumor expression profiles

Interestingly, these subgroup-specific alterations included amplifications and
homozygous deletions of genes not yet implicated in ependymoma. In order to validate
candidate oncogenes, they first identified cellular compartments most likely to give rise
to subgroups of ependymoma. This was done by using AGDEX
5

algorithm which detects transcriptomic similarities between tissues from different species
by comparing the expression of shared orthologues (Pounds et al., 2011b). Using the
AGDEX, the transcriptomes of human tumors were then matched to those of mouse
neural stem cells (NSCs), isolated from different regions of the CNS at different
developmental stages, with an intact or deleted Ink4a/Arf locus. The transcriptome of
human supratentorial ependymomas with amplified EPHB2 and deleted INK4A/ARF
matched only that of embryonic cerebral Ink4a/Arf(-/-) NSCs. EPHB2 receptors are
members of the Eph family of transmembrane proteins. They possess an extracellular
domain that recognizes signals from the cells' environment which influences cell-cell
interaction and cell migration. Eph receptor and ephrin (Eph ligands) overexpression can
result in tumorigenesis as related to tumor growth and survival and is associated with
angiogenesis and metastasis in many types of human cancer (Adams et al., 2001; Hynes,
1992; Maulik et al., 2002; Palmer et al., 2002; Wang et al., 1998). Only the activation of
Ephb2 signaling in embryonic cerebral Ink4a/Arf(-/-) NSCs but not other, NSCs
generated the first accurate mouse model of ependymoma. Recently, subsequent models
of ependymoma have been established by using a novel pooled approached for screening
ependymoma candidate oncogenes (Murugensan et al. Unpub.). Murugensan et al.
generated 84 RFP-tagged retroviruses encoding each ependymoma oncogene candidate
and transduced these into neural stem cells (NSCs) which were then pooled into 11 pools.
The pools of cells were then orthotopically implanted into immunocompromised mice.
Using this approach they identified AKT2, PSPH (pool-1), BCL7C, TMEM129 (pool-2),
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TTC9B, RAB3A, ERICH1 (pool-3), RTBDN, CTF1, VKORC1 (pool-4), RNASE2H,
PRDX2 (pool-6) and ARRDC2, PRDX2 (pool-8) as enriched ependymoma oncogenes.
Validation of these genes by single oncogene approach confirmed RTBDN, RAB3A,
ZNF668, BCL7C, MRPS17, and TMEM129 as oncogenes.
Treatment. Currently, ependymoma treatment is solely based on surgery and
radiotherapy, with a 5-year survival rates as high as 70.8% in adults (Meco et al., 2014).
In contrast, prognosis is markedly worse in children, because of the unlikelihood of gross
total resection and the use of radiotherapy in very young patients is limited because of
adverse side-effects (Koos et al., 2011). Additionally, there are no known effective
conventional chemotherapies that have been identified (M. E. a. G. R. Merchant, 2010).
However, preclinical studies have shown some promising results at slowing tumor
growth (Atkinson et al., 2011; Meco et al., 2014)
In a study conducted by Atkinson et al. (2011), the ephB2 mouse model of
ependymoma was used in combination with multicell high throughput screening (HTS),
kinome-wide binding assays, and in vivo efficacy studies, to identify potential treatments
with predicted toxicity against neural stem cells (NSC). The screen identified kinases
within the insulin signaling pathway and centrosome cycle as regulators of ependymoma
cell proliferation, and their corresponding inhibitors as potential therapies. Importantly,
5-fluorouracil, an FDA approved drug, not currently used to treat ependymoma was also
identified. The drug showed selective toxicity against ependymoma cells relative to
normal NSCs both in vitro and in vivo and is now in stage 2 of clinical trial (Figure 2).
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Figure 2. 5 FU demonstrating in Vivo Efficacy against mEPEphb2. Panels to the left
show serial weekly bioluminescence scans of a single representative animal treated with
the corresponding drug the mean (±SD) weekly fold change in tumor bioluminescence
at that time point differs from that observed in the control group. Graphs to the right
report survival of drug (red line) versus control (black line) treated mice in each cohort.
In both graphs *p=0.05 **p=0.005 ***p=0.0005 for the corresponding statistic
(Atkinson et al. 2011;6).

Glioblastoma
Incidence and pathology. Gliomas represent over a half of all childhood neoplasms
(Pollack, 1994; Young, Ries et al., 1986). They make up 60% supratentorial tumors,
50% of supratentorial midline tumors, and 40% infratentorial tumors (Pollack, 2010).
Most of these tumors are World Health Organization Grade I or II astrocytomas (37).
Clinical outcomes of this disease vary based on tumor grade and the extent of resection
with complete removal resulting in excellent prognosis. However, patients with
inoperable tumors have a poor prognosis (Pollack et al., 2003).
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Malignant gliomas (glioblastomas) are divided into anaplastic astrocytoma (gradeIII),
mixed glioma, oligodendroglioma, and glioblastoma multiform (gradeIV) (Pollack,
2010). Pediatric high-grade gliomas (pHGG) are rare in children with the exception of
the brainsteam where malignant diffuse tumors are more common than lower grade
tumors (Korshunov et al., 2009). Over 90% of children with diffuse intrinsic pontine
glioma (DIPG) succumb to their disease within 2 years of diagnosis (Bartels et al., 2011).
These tumors are not amenable to surgical management, and there is no evidence that
radiation therapy, or chemotherapy improves patient survival (Kaplan et al., 1996;
Mandell, 1999).
Molecular biology of glioblastoma. In 2010 the Cancer Genome Atlas (TCGA)
cataloged recurrent genomic abnormalities in GBM identifying TP53, RB1, PIK3R1,
NF1, and ERBB2 as the most common mutations (Verhaak et al., 2010). Using the data
from the TCGA, Verhaak et al., compiled an in depth gene based molecular classification
of GBM into proneural, neural classical, and mesenchymal, and somatic subtypes which
are characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 (Verhaak et al.,
2010). The research conducted by Strum et al. (2012) showed that these genes
representing each subgroup were associated with cell cycle regulation (HC1 subgroup),
with neuronal differentiation (HC2 subgroup), and with extracellular matrix–receptor
interactions and cell adhesion (HC3 subgroup). The analysis also identified H3F3A, a
gene encoding histone 3, to be commonly mutated in 78% of patients with DIPG. Strum
et al. (2014) used an integrative approach based on epigenetic, copy number, expression,
and genetic analyses to investigate the heterogeneity of glioblastoma across all age
groups. Using this approach, Strum et al. (2012) was able to separate high grade glioma

9

into six different subgroups (Sturm et al., 2012) (Figure 3). Other groups have also
identified molecular pathways and possible therapeutic targets against DIPG (Gilbertson
et al., 2003; Paugh et al., 2010; Jeremy Schwartzentruber et al., 2012). For example, the
over expression PDGFRA was found to be the most common genomic event in pHGG
(Paugh et al., 2010; Zarghooni et al., 2010). Also, patient samples revealed that tumor
suppressor genes such as P53, NF1, RB1, are the most commonly deleted in pHGG
(Cheng Y, 1999; Kraus, 2001; Schwartzentruber et al., 2012; Suri et al., 2009).
Transgenic animal models of glioblastoma. There are several mouse models of
glioma representing the core altered pathways in glioblastoma identified by TCGA (5258). The mesenchymal model is represented by the loss of NF1 (52,53). Zhu et al. (2005)
generated mouse strains that lack p53 and contain a conditional allele of the NF1 tumor
suppressor that negatively regulates Ras signaling. Their mouse model developed
malignant astrocytomas with complete penetrance. The majority of tumors displayed
characteristics of glioblastoma multiforme with associated alteration of signaling
pathways previously described in the human counterparts of this neoplasm (Zhu et al.,
2005).
The classical glioblastoma model is represented by the EGFR amplification/Ras
activation model (Holland et al., 2000; Holland, Hively, DePinho, & Varmus, 1998).
Holland et al. (1998) demonstrated that the expression of a constitutively active, mutant
form of EGFR in cells in the glial lineage that have a disrupted INK4a–ARF locus can
induce lesions with many similarities to human gliomas. In a study conducted by Holland
et al. (2007), genes encoding activated forms of Ras and Akt were transferred into
astrocytes and neural progenitors in mice. Although neither activated Ras nor Akt alone
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was sufficient to induce glioblastoma multiform GBM formation, the combination of the
two induced high-grade gliomas with the histological features of human GBMs.
The proneural glioblastoma model is represented by PDGF amplification (Deinhardt
et al., 1972; Uhrbom, Hesselager, Nister, & Westermark, 1998). Deinhardt et al. (1972)
showed that simian sarcoma virus mediated over expression of PDGF induced the
formation of gliomas in the brains of marmosets (Deinhardt et al., 1972). Uhrbom et al.
(1998), used a murine retrovirus containing the PDGF B-chain to induce brain tumors in
mice. Of the 35 mice who received the injections, 15 developed brain tumors of oligo- or
monoclonal origin. Most tumors displayed characteristics of GBM or of a primitive
neuroectodermal tumor (Uhrbom et al., 1998).
Xenograft models of glioblastoma. Immunodeficient rodents have provided an
important tool used in modeling human GBM (Rana et al., 1977). Growing and
examining of GBM in such animals is most commonly accomplished in the subcutaneous
flank location (heterotopic) (Giannini et al., 2005). However, recent years there has been
an increased use of orthotopic (intracranial) xenograft models (Janbazian, et al., 2014).
For both heterotopic and orthotopic studies, xenograft tumors are usually established
from permanent human GBM cell lines (Giannini et al., 2005). Unfortunately, xenograft
models that use this approach do not recapitulate key GBM characteristics like invasion
and fail to over express EGFR (Finkelstein et al., 1994; Pilkington et al., 1997; Saris et
al., 1984; Tonn, 2002). However, Sarakaria et al (2006), demonstrated that glioblastoma
xenografts established directly from patient surgical specimens and that are maintained as
s.c. xenografts through serial passaging in immune-deficient mice is the only means that
has been shown to preserve tumor EGFR amplification status (Sarkaria et al., 2006).
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Also, isolated CD133+ glioma tumor cells when implanted into immunedeficient mice
produced tumors that were invasive (Bao et al., 2006). Our lab produced a glioblastoma
mouse model by transducing NSC’s with ERBB2 and implanting these cells
orthotopically into CD1 nude mice. Tumors formed within two weeks that genetically
and histologically matched that of the human disease.
Zebrafish models of glioblastoma. Yang et al. (2013) developed a novel zebrafish
embryo xenograft model to analyze the invasion and spread of human glioma cancer stem
cells (GSCs). Larval fish were implanted in the yolk sac with RFP positive malignant
glioma cells obtained from a commercially available cell line (U87). They demonstrated
that GSCs derived from human glioblastoma cell line U87 possessed a highly invasive
phenotype characteristic of the disease (Yang et al., 2013). In a follow-up study by Yang
et al. (2014), they examined the biological features of glioma stem cells (GSCs) in a
larval zebrafish, such as tumor angiogenesis, invasion, and proliferation. Their results
demonstrated that several verified anti-angiogenic agents inhibited angiogenesis that was
induced by xenografted-GSCs (Yang et al., 2014). Jung et al. (2012) established a
zebrafish transgenic glioblastoma model through overexpression of dominant-active
(DA) human Akt1 or Rac1G12V (DARac1) at ptf1a domain and investigated transgenic
phenotypes and mechanisms leading to gliomagenesis. The fish produced tumors with a
36.6% penetrance at 6 and 9 months (I. H. Jung et al., 2013).
Treatment of glioblastoma. The current therapy for malignant supratentorial
glioma for children older than three is resection followed by radiation of the tumor bed
using a dose of 5000-6000c Gy combined with some form of chemotherapy (lomustine,
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vincristine, and prednisone) (Pollack, 2010). Like other brain tumors, the extent of
surgical resection dictates patient outcome.
Erlotinib has been used for glioblastoma treatment in tumors that over express the
EGFR (Custodioet al., 2010).

The epidermal growth factor receptor (EGFR) is a

transmembrane glycoprotein that constitutes one of four members of the erbB family of
tyrosine kinase receptors. The binding of EGFR to its cognate ligands leads to
autophosphorylation of receptor tyrosine kinase and the activation of signal transduction
pathways that are involved in regulating cellular proliferation, differentiation, and
survival (Herbst, 2004). Activation of EGFR has been associated with involvement of
tumor pathology such as growth and progression, including cell proliferation, inhibition
of apoptosis, metastasis and angiogenesis (Dancey & Sausville, 2003). EGFR is
commonly overexpressed in glioblastoma as well as the majority of solid tumors (Herbst
& Langer, 2002; Verhaak et al., 2010). Erlotinib competes with the binding of ATP to
the intracellular tyrosine kinase domain of EGFR inhibiting receptor autophosphorylation
which blocks downstream signal transduction (Moyer et al., 1997; Pollack et al., 1999).
Tyrosine kinase inhibitors like erlotinib have shown to be an effective treatment for the
control of GBM and other brain tumors that over express EGFR (Gadji et al., 2009;
Halatsch et al., 2006; Martens et al., 2008).
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Figure 3. Hotspot Mutations in H3F3A and IDH1 Define Distinct
Epigenetic and Biological Subgroups of Glioblastoma (used with
permission, Strum et. al. 2012) .

Choroid Plexus Carcinoma
Incidence and pathology. Choroid plexus papillomas (CPPs) are relatively rare
neuroectodermal tumors that develop from choroid plexus epithelial cells and account for
0.4–0.6% of all primary brain tumors (Rickert & Paulus, 2001). Within this family of
tumors, there are benign and malignant forms, classified as either choroid plexus
papilloma (CPP) or choroid plexus carcinoma (CPC), respectively (Gopal et al., 2008).
CPC is classified as a highly aggressive malignant tumor according the World Health
Organization (WHO grade III) (Gopal et al., 2008) . They are an aggressive neoplasm
which arise from the choroid plexus epithelium and are characterized by papillary and
intraventricular growth (Rickert & Paulus, 2001). The occurrence is mainly in children

14

between the ages of 26-32 months with the survival rate of 40% (Berger et al., 1998).
There is currently no established protocol for the treatment of CPC; however, complete
resection of the tumor is the primary goal. Gross total tumor resection gives the best
chance of survival and improves overall prognosis, but unfortunately complete tumor
resection is achieved in only 40% to 50% of children with CPC (Dickens, 2005; Packer,
1992; Pierga, 1993). Unfortunately, complete resection of this tumor is associated with
high morbidity due to such factors as patient age, widespread tumor dissemination, and
tumor vascularity (Pierga JY, 1993) .
Molecular biology. Similar to most other cancers, CPC is associated with loss of
function of p53 protein and is found in over 50% of cases (Tabori et al., 2010;
Zakrzewska et al., 2005). Tabori et al. (2010), established a multi-institutional tissue and
clinical database, enabling the analysis of specific alterations of the TP53 tumor
suppressor and its modifiers in choroid plexus tumors (CPTs). They conducted highresolution copy-number analysis in order to correlate these genetic parameters with
family history and outcome. They concluded that patients with CPC, who have low tumor
total structural variation (TSV) and absence of TP53 dysfunction have a favorable
prognosis and can be successfully treated without radiation therapy (Tabori et al., 2010).
Although currently there are no promising chemotherapies, several chromosomal gains
and deletions have been identified that may lead to targeted therapeutics in the future
(Kamaly-Asl, Shams, & Taylor, 2006). For example, Rickert, Wiestler, & Paulus (2002),
used conventional comparative genomic hybridization revealing a number of
chromosomal imbalances (mainly +12, +20p, +1, +4q, +20q, -22q, -5, -18) (Rickert et al.,
2002).
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Available mouse models of CPC. Our lab has produced the first choroid plexus
carcinoma model in mice by creating a conditional knockout using electroporation of Cre
into the choroid plexus of mice on a triple floxed background (p53, p10 and RB; Tong.
Unpub.). Remarkably, this model is both genotypically and histological similar to the
human disease. The cell line derived from this model is currently being used for high
through put drug screening in hopes of identifying an effective compound against this
disease.
Creating Preclinical Cancer Models
There are currently over 100 different types of cancer and with the advancements in
genomics the number is increasing as new subgroups are being identified in each
different organ (Hanahan & Weinberg, 2000). In order to identify drugs that are
effective against these cancers, clinically relevant models of these diseases are critical
(Hoffman, 2001; Holland, 2004). This is exemplified by the fact that anticancer drug
discovery and development is an inexact and inefficient process, with 89% failing to
acquire FDA approval (Kola & Landis, 2004). Sharpless and Dephino (2006) believe
that the solution lies in the use of refined models of human cancer that are capable of
facilitating the identification of the right target, the right drug and the right mutations
(Sharpless & Depinho, 2006). This means that each cancer subgroup requires an accurate
model for relevant drug testing. Because of the heterogeneity of cancer, accurate
preclinical cancer models are required to validate novel targets, to evaluate drug
candidates, and to understand the mechanisms of resistance to therapy (Martell, Brooks,
Wang, & Wilcoxen, 2013) . In order for the preclinical cancer models to be effective,
they need to be produced with high penetrance and they need to genetically resemble the
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human disease (Huse & Holland, 2009). Currently there are three different methods for
creating tumor models: 1) the genetically engineered models (GEMM), 2) the xenograft
model, and 3) the allograft model. The first modeling system uses genetically engineered
models (GEMM) in which the genetic profile of the model is altered such that one or
several genes thought to be involved in transformation or malignancy are mutated,
deleted or overexpressed (Richmond & Su, 2008). The second modeling system, the
tumor xenograft model uses immunocompromised animals as surrogate hosts for
transplanted tumor tissue or cells (interspecific). The third model, the allograft model, is
intraspecific, in which tumor tissue or cells are implanted into immunocompromised
animals (Richmond & Su, 2008).
The Merits of Each Model System
Genetically engineered models. There are several advantages GEMMs have over
the other model systems: (1) the mice are immunocompetent, allowing for the
maintenance of an intact tumor microenvironment; (2) specific genetic abnormalities that
are present in human cancers can be replicated, in tissue-type of origin; (3) the stages of
tumor progression can be examined closely; and (4) drug testing can be conducted at
various stages of tumor development (Richmond & Su, 2008). Possibly the main
advantage the GEMMs have over the other models is that researchers can examine
mutations that drive de novo formation of tumors in the correct microenvironment (van
Miltenburg, 2012). Also, GEMMs provide an in vivo approach for confirming oncogenes
and/or tumor suppressor genes (Richmond & Su, 2008). However, there are also several
draw backs of GEMMs: (1) The majority of GEMMs exhibit long tumor latencies and/or
have inadequate penetrance for drug screening (Huse & Holland, 2009), 2) development
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is costly and time consuming, and (3) there is difficulty in producing large cohorts of
tumor bearing animals that are readily and consistently available for drug screening
(Becher & Holland, 2006; Singh, 2006). This is exemplified by the transgenic
glioblastoma models mentioned above, with the majority of tumors taking months or
even up to a year to form (52-58,69). The glioblastoma model established by Jung et al.
(2013) in zebafish was created by dominant active (DA) DAAkt1 (Jung et al., 2013).
However, the expression of AKT alone was insufficient to induce glioblastoma in mouse
models (Gladson, Prayson, & Liu, 2010; Holland et al., 2000). This discrepancy might
be a result of the fish being more susceptible to AKT mutation due to differences in cell
signaling events, however an in depth genetic analysis is needed to have better
understanding of the difference. It has been noted that overall, the tumor incidences (
around 30%) in zebrafish are generally lower and the onset is later as compared with the
orthologous mouse models (Feitsma & Cuppen, 2008). Also, a recurrent problem in
zebrafish transgenic models is the presence of duplicated genes resulting from recent
partial or complete genome duplication in teleosts which may influence the role of
oncogenes and tumor suppressors in tumorogenesis (Furutani-Seiki & Wittbrodt, 2004).
Mouse Xenograft/Allografts Tumor Models
The transplantability of cancer cells has addressed important key aspects of tumor
biology, such as malignancy, metastasis and cancer stem cell biology (Taylor & Zon,
2009). Xenograft modeling represents the most frequently used modeling system (Huse &
Holland, 2009). In this system, tumor tissue (or tumor cells) from a different species are
implanted into an immunocompromised species either orthotopically (in native tissue) or nonorthotopically (i.p. or s.c.). There are many advantages when using this system for preclinical
trials. For example, therapeutics can be tested on human tissue, xenografts can be used for
18

personalized therapeutic testing, and results can be evaluated quickly (Richmond & Su, 2008).
Additionally orthotopic xenograft models are known for their ability to recapitulate the pathways
of metastasis seen in human head and neck cancers (Sano & Myers, 2009). The main
disadvantage of this system is that immunocompromised models provide a less realistic
microenvironment (Quentmeier, Osborn, Reinhardt, Zaborski, & Drexler, 2001).

Allograft (same species) models are also a frequently used system for modeling
tumors. In this system murine derived tumor cells or tissue is transplanted into a mouse
host. Because the transplanted tissue originated in the same species, rejection is
minimized. Although mouse tissue lacks the complexity of its human counterpart, the
intraspecific physiological environment of the transplanted tissue is maintained to a
higher degree when using the same species. Therefore, the worry of cell signaling
conservation, which is uncertain when using xenografts, is minimized (Chou et al., 2013).
For the reasons mentioned above, the xenograft/allograft models of glioblastoma,
ependymoma, and choroid plexus carcinoma are readily used for drug screens in mice
(Atkinson et al., 2011; Johnson et al., 2010a; Joo et al., 2013; Sarkaria et al., 2006;
Uchida et al., 2013; Xie et al., 2008). Interestingly, the fish model of glioblastoma Yang
et al. (2013) demonstrated invasion remarkably similar to its human counterpart and
hundreds of tumor bearing individuals were produced.
Preclinical Drug Testing
High-through put screening. High through-put drug screening (HTS) uses
automation to enhance speed, sensitivity, lower cost and efficiency allowing the
researcher to potentially screen tens of hundreds of thousands of compounds in a single
day (Martell et al., 2013). A variety of technologies can be used with the system such as
fluorescence-based techniques, detection platforms, liquid-handling technologies,
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microarrays, chromatography, and nuclear magnetic resonance (Szymanski et al., 2012).
When utilizing the HTS against cancer cells looking for cytotoxicity, an initial primary
screen is conducted to identify hits based on a single dose set to a specific activity cut-off
threshold (Atkinson, 2011). Then potency is assessed in a secondary screen in a
concentration dependent manner for the compounds that passed the primary screen
creating a list of potential ‘hits” that can go on to be tested in mice, the next phase of
preclinical trial. For example, Atkinson et al. (2010), conducted a drug screen against
cells derived from a mouse model of ependymoma as well as control cells. The screen
involved using a total of 7,890 (5,303 unique) compounds obtained from seven separate
sources, divided among four libraries: a ‘‘bioactive’’ library that included 5,600 (3,161
unique) bioactive compounds, natural products, and known drugs; a ‘‘kinase-scaffold’’
library composed of 1,648 compounds designed using kinase inhibitor pharmacophore
models; GlaxoSmithKline’s Published Kinase Inhibitor Set (GSK-PKIS) composed of
367 kinase inhibitor tool compounds with good bioavailability and known specificity;
and a Food and Drug Administration (FDA) library that included 275 FDA approved
compounds that were enriched for anticancer and neurologically active drugs. The screen
resulted in the identification of kinases within the insulin signaling pathway and
centrosome cycle as regulators of ependymoma cell proliferation, and their corresponding
inhibitors as potential therapies. Interestingly, FDA approved drugs not currently used to
treat ependymoma were also identified that possess selective toxicity against
ependymoma cells relative to normal NSCs both in vitro and in vivo, e.g., 5-fluorouracil
(Atkinson et al., 2011).
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The HTS bottleneck. Although hundreds of potential therapeutics are rapidly
identified as a result of the in vitro portion of the screen, the in vivo phase of the screen is
unfortunately much slower creating a “bottleneck” the screening process (Gosai et al.,
2010; Lindsay, 2003) . This is due to only a handful of potentially hundreds of hits
identified in the secondary screen being able to be tested at a time in mouse models
because of: 1) cost constraints involved not only in maintaining an immunocompromised
colony, but also testing expensive therapeutics on these mice, and 2) the length of time it
takes to produce sufficient numbers of models, to assess drug response, and to conduct
PK analysis to assess pharmacokinetics and pharmacodynamics in the mice. This
facilitates the need for an additional intermediate step to streamline the HTS process to
identify drugs that are efficacious in a whole animal system before the drugs are triaged
to mice (Parng, Seng, Semino, & McGrath, 2002; Serbedzija, Flynn, & Willett, 1999).
Zebrafish have been shown to develop many types of cancers which are histologically
and pathologically similar to human cancer (Stoletov & Klemke, 2008). This combined
with the fact that zebrafish are inexpensive to maintain, breed in large numbers (can have
between 100-300 transparent embryos per breeding), develop rapidly ex vivo, and can be
maintained in small volumes of water make them ideal candidates for bridging the HTS
gap. However, zebrafish brain tumor models would have to meet several critical criteria
in order to effectively “bridge the gap” between cell culture dish and mice: 1) the model
would have to be genetically similar to the pre-clinical mouse model in order to identify
relevant hits, 2) Because of the potentiality of obtaining large numbers of secondary
hits , the intermediate zebrafish model would have to be able to be produced quickly and
in large numbers, 3) the model would have to be large enough in size order to undergo
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genetic and histological scrutiny, 4) The model would have to have fully functional organ
systems in order to be synchronous with the adult mouse model, 5) the researcher would
have to be able to easily track tumor growth in order to access drug response, and 6) the
model would have to respond to the majority of the same drugs as its mouse counterpart
in order to be effective. Producing zebrafish xenograft models may provide the best
outlet to fulfilling the above criteria.
The Argument for Using Zebrafish Xenografts as a “Bridging Species”
Zebrafish xenograft models have been developed. Recent studies have provided
proof of principle that zebrafish can act as efficient hosts for xenografts of human cancers
(Lee et al., 2005; Topczewska et al., 2006) For example, several studies have shown that
human melanoma cells survive and exhibit cell motility when transplanted in zebrafish
(Lee et al., 2005; Topczewska et al., 2006). Similarly, Haldi et al. (2006) observed
masses, in the abdominal cavity as well as the brain when xenografting human melanoma
cells in slightly older zebrafish. These models are also useful for studying cell signal
events critical in the development of certain tumors. For example, Topczewska et al.
(2006) demonstrated that zebrafish embryos could act as a biosensor for tumor-derived
signals by responding to the potent tumor-derived embryonic morphogen, Nodal. Further
experiments showed the presence of Nodal in human metastatic tumors. Also, when
Nodal signaling was inhibited in the zebrafish xenografts, there was a reduction in
melanoma cell invasiveness. Therefore zebrafish that maintain the basic environments of
tissues while allowing, because of less technical and financial constraints, the study of
larger numbers of tumors could be very advantageous.
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Maintenance of tumor fidelity in fish xenografts. Drabsch et al. (2013), used
breast cancer cell lines of which, in previous studies, they and others have shown that the
invasive and metastatic behavior in invasion and mouse xenograft models is dependent
on TGF-β (Drabsch et al., 2013). They demonstrated that the invasive and metastatic
behavior, corresponding with the cell grade of malignancy can be recapitulated within the
zebrafish. Interestingly, the effects obtained after the inhibition with TGF-β receptor and
Smad function in fish mimicked the effects observed in mice (Drabsch et al., 2013). In
another study by Jo et al. (2013), orthotopically injected retinoblastoma cells were
scanned daily under confocal microscope, and the tumor population was quantitatively
analyzed by measuring the mean intensity of green fluorescent protein (GFP). These
transplanted retinoblastoma cells maintained their proliferative potential and
characteristics as retinoblastoma cells after isolation (Jo et al., 2013).
Zebrafish xenografts respond to drugs. Through the years, zebrafish have been
shown to be effective screening tools against a wide range of compounds (Zon &
Peterson, 2005; Mimeault, 2012; Taylor, Temperley, & Patton, 2010; Zhu, Rodig, &
George, 2012). Earlier chemical studies utilized zebrafish primarily for toxicological
studies (Ruoppa, 1988); with the advent of zebrafish cancer models, zebrafish have
shown great promise for anti-cancer drug screens recently. For example, Yigen and
colleagues (2012) , demonstrated that zebrafish embryos could successfully be used for
testing chemotherapeutic toxicity. In their study a library of 502 natural compounds were
screened against zebrafish embryos and the results were compared with those from an
MTT assay of the MCF7 breast cancer cell line. The screen identified 59 toxic
compounds, 21 of which were also identified by the MTT assay, and 28 of which were
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already known for their anti-cancer and apoptosis-inducing effects (Y. G. Li et al., 2012).
In another study, Ridges et al. (2012), screened a small molecule library for activity
against a zebrafish model of T-cell acute lymphoblastic leukemia (T-ALL). After
screening 26,400 molecules, they identified Lenaldekar (LDK), a compound that
eliminates immature T cells in developing zebrafish without affecting the cell cycle in
other cell types (Ridges et al., 2012). Importantly, LDK is well tolerated in vertebrates
and induces remission in adult zebrafish with T-ALL. Additionally, Kitambi et al.
(2012), showed that a small molecule screening platform was successfully used against
adult zebrafish to assess cardiovascular toxicity (Kitambi et al., 2012) . Many other
successful screens have been conducted utilizing zebrafish either to identify effective
compounds for a range of diseases or to use various compounds to modulate certain
diseases to better understand them (Laggner et al., 2012; Peterson et al., 2004). Jo et al.
(2013) screened an orthotopic model of retinoblastoma against two currently utilized
clinically relevant drugs used against retinoblastoma, carboplatin and melphalan.
Interestingly, both drugs demonstrated effective anticancer activity on this model.
Furthermore, they produced more than 200 zebrafish models of retinoblastoma in a single
sitting; therefore, more than 20 different candidate drugs can be screened with 1 session
of experiments (Jo et al., 2013) .
As a result of the above studies, we hypothesize that zebrafish xenografts are an
excellent model in which to model pediatric brain cancer and “bridge the gap” between in
vitro and in vivo drug screening. We tested our hypothesis by completing three specific
aims:
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Aims
Aim 1: Model brain tumors in zebrafish. The overall goal of this aim is to
produce brain tumors in zebrafish through orthotopic transplantation of accurate mouse
models of human brain tumors. We will inject mouse brain tumors derived from
transformed neural stem cells (NSCs) into fish brain and assess their capacity to form
tumors in vivo. For controls, adult fish will be injected with control transduced NSCs.
Aim 2: Characterize tumor model. All tumor models established in Aim 1 will be
subjected to comprehensive growth, histological and molecular analysis to confirm that
they retain the status of accurate models of the corresponding human disease. This will
include the use of our novel algorithm, Agreement of Differential Expression (AGDEX)
that detects transcriptomic similarities between tissues from different species by
comparing the expression of shared orthologues. This aim is important in order to assess
the drug testing relevancy of the models.
Aim 3: Assess the response of zebrafish brain tumors to novel and existing
therapies. We have identified a series of therapies (both existing and novel) that are
active against our mouse brain tumor models. In this aim we will use the models
developed in Aims 1 and 2 to test the efficacy of therapies against brain tumors in
zebrafish. Zebrafish with tumors will be treated with various doses and schedules of
drugs shown to be efficacious against these same tumors in mice. Comprehensive
assessment of the impact of the drugs on tumor growth, fish survival as well as drug
pharmacokinetics will be performed. These experiments will provide important proof-ofprinciple regarding the value of the fish model for therapeutic studies.
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Chapter 2
General Materials and Methods
Cell Culture
Blbp–eGFP transgenic mice were the generous gift of N. Heintz. The mice were then
breed onto an ink4a/Arf-/- background. The eGFP+ neural stem cells (NSC’s) were
isolated from the mouse brains and immediately following surgical resection, brain tissue
was minced and digested with collagenase type IV and hyaluronidase for 60 min at 37°C.
Cells were then grown as suspension cultures in Neurobasal medium (Invitrogen)
containing 2 mM L-glutamine, N2 supplement (Invitrogen), B27 supplement
(Invitrogen), 20 ng/ml hrEGF (Invitrogen), 20 ng/ml hrbFGF (Invitrogen) and 50 g/ml
BSA in 5% CO2 (25). Cells were sorted for eGFP using a Becton Dickinson Aria II Cell
Sorter.
Tumor Cell Line Generation
The mouse model of glioblastoma was generated by transducing Blbp–eGFPink4a/Arf-/mouse embryonic neural stem cells (NSC) with an ERBB2-RFP retrovirus (GBMERBB2RFP). Two separate ependymoma models were generated from NSC transduced with
RTBDN-RFP (EPRTBDN-RFP) or EPHB2-RFP retroviruses (EPEPHB2-RFP). We also
isolated cells from a new mouse model of choroid plexus carcinoma that we recently
developed by transducing the choroid plexus of embryonic Tp53flx/flx;Rb flx/flx;PTEN
flx/flx mice with Cre-recombinase-RFP (CPCRFP,unpublished). CD1 nude mice were
then implanted into the lateral forebrain with the transduced cells and produced tumors
histologically and genotypically validated as glioblastoma, ependymoma, and choroid
plexus carcinoma (Johnson et al. 2010 ). The RFP+ neural stem cells (NSCs) were
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isolated from the mouse brains and immediately following surgical resection, brain tissue
was minced and digested with collagenase type IV and hyaluronidase for 60 min at 37°C.
Cells were then grown as suspension cultures in Neurobasal medium (Invitrogen)
containing 2 mM L-glutamine, N2 supplement (Invitrogen), B27 supplement
(Invitrogen), 20 ng/ml hrEGF (Invitrogen), 20 ng/ml hrbFGF (Invitrogen) and 50 g/ml
BSA in 5% CO2 (25). Cells were then sorted for RFP using a Becton Dickinson Aria II
Cell Sorter.
Fish
Adult zebrafish (ranging in age from 3-6 months) on AB wild type, Fli1:EGFP, were
used for these experiments. The Fli1:EGFP fish were used in order to visualize blood
vessel development.
Preparing Cells and Implantation Procedure
Dissociated cells were prepared in cell suspension (1 x 106 cells/5µl of neural basal
media). Fish were anesthetized using 0.04% (40ml) tricaine in a petri dish. Under a
reflected light dissecting scope, fish were gently held using forefinger and thumb then
injected intranasally with 1 µl of cell suspension (2 x 105 cells) using 30 gauge Hamilton
syringe. Implanted fish were placed into clean breeder tank with 1 liter of fish water
containing 15 µg/ml dexamethasone, placed back into the 40 gallon at 35°C where they
were monitored for signs of post implantation stress (rapid respiration, erratic swimming)
and immediately euthanized on wet ice if signs of stress occur.
Collection of Tissue for Histological Assessment
Fish were euthanized by placing them into 0.04% tricaine until gills stop moving and
then decapitated using a scalpel. For immunohistochemistry, tissues were drop fixed into
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10% formaldehyde overnight, placed in 70% ETOH and paraffin embedded. For
immunofluorescence, tissue were placed in 4% paraformaldehyde overnight, cryoprotected and frozen in TFM™.
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Chapter 3
Stereomicroscopy versus Xenogen
Ability to monitor the growth of tumor cells in vivo is essential to establish the pattern
of growth for potential use of these models in preclinical drug testing (Gros et al., 2010;
Hoffman, 2005, 2009). Xenogen imaging allows the researcher to track tumor growth
either using bioluminescence or fluorescence. The advantage of the system is that you
can image multiple animals at time,
allowing for a more high-through put
approach for assessing tumor growth
(Atkinson et al., 2011; Winnard, Kluth, &
Raman, 2006). This system is ideal for
imaging large cohorts of tumor bearing
animals such as zebrafish. In order to
assess the best method for tracking tumor

Figure 4. A xenogen image taken of
zebrafish implanted with RFP positive
GBM cells. (The top fish is used as a
negative control).

growth, we compared two different
methodologies (xenogen imaging versus
standard fluorescence stereomicroscopy

imaging) to determine which would result in the most consistent method of tracking
tumor growth. Our hypothesis is that xenogen imaging would the most accurate and
quickest method for imaging large cohorts of fish. To test this hypothesis a group of 94
tumor bearing fish was imaged in groups of 5 using xenogen (Figure 4). Another group
of 12 fish was imaged as single specimens using a camera attached to a fluorescent

29

stereomicroscope. Both groups of fish were imaged at three time points: day 1, day 3
and day 5, post injection.
Methods
Implantation of cells. A total of 106 adult AB fish were implanted intracranial with
2 ×105 GBMERBB2-RFP cells (methods described in detail in chapter 5)
Monitoring tumor growth using intravital microscopy. In order to track growth of
implanted cells, 3-5 fish were anesthetized using 40mls of 0.04% tricaine in a 100 mm
cell culture dish. Fish were then transferred using a spatula onto a 100mm cell culture
dish lid (Corning®) which rested on the stage of the stereomicroscope (Zeiss). Fish were
positioned dorsal side up and imaged (Nikon) individually using wavelength 580nm,1.6
X magnification, at1.13 second exposure for the detection of RFP. Imaging took place
on post injected days 1, 3, and 5. Mean intensity of fluorescence was measured at each
time point fish were imaged using NIS Elements Br (Nikon) and plotted using GraphPad
Prism 6.
Monitoring tumor growth using Xenogen imaging. Fish were imaged using a
xenogen imaging system, which measures photon emissions from the fluorescent label of
the cells in the Region of Interest (ROI). ROI defines the area from which the number of
photons being emitted from the source is calculated. A group of 5 were not implanted
and used for background control. The fish were then anesthetized in 0.04% tricaine and
placed on top of culture dish lids in groups ranging between 3-5. A control, nonimplanted fish was placed at the top of the lid and used for background control. The fish
were then imaged and placed back in fresh water containing 15 µg/ml of dexamethasone.
Fish were xenogen imaged on day 1, 3, and 5. A Mann-Whitney test was conducted
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looking for significant increase in tumor growth over the 5 day period using GraphPad
Prism 6.
Statistical Comparison. For stereomicroscopy, mean intensity of fluorescence was
measured at each time point using NIS Elements Br (Nikon). For Xenogen imaging,
photons per second were cataloged and a Mann-Whitney test was conducted looking for
significant increases in tumor growth over the 5 day period. Coefficient of variation was
used to determine which method was the most reliable.
Results and Discussion
Fluorescence stereomicroscopy is more precise in tracking tumor growth than
xenogen imaging. For the zebrafish system to work as an effective model, the ability to
reliably track tumor growth quickly is critical for 3 reasons: 1) for minimizing mortality
from both prolonged anesthesia and being removed from water 2) ability to image large
cohorts that can be generated in zebrafish in a timely manner and 3) ability to determine
drug efficacy. In order to assess which is a more reliable method for tracking tumor
growth in the fish models, we tested two different imaging methods, fluorescence
stereomicroscopy and xenogen imaging. Xenogen imaging would allow fish to be
imaged in groups of 5 unlike stereomicroscopy in which only a single fish could be
imaged at a time. However, xenogen imaging resulted in higher coefficient of variation
than stereomicroscopy (day1:cv= 0.435, day2: cv= 0.969, day3: cv=0.974) compared to
stereomicroscope imaging (day1: cv=0.25, day2: cv=0.227, day3: cv=0.30; Figure 5).
Considering xenogen was developed for the imaging of small mammals, zebrafish maybe
below the detection threshold of the instrument. Even though xenogen imaging is not
reliable for tracking tumor growth, it still could be useful for determining presence or
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absence of tumor (as illustrated in chapter 2). Surprisingly, stereomicroscopy imaging
was not much more time consuming (around thirty seconds per fish) and resulted in zero
mortality.

Figure 5. A comparison between xenogen imaged (photons/sec) and stereomicroscope
imaged (mean intensity) tumor bearing fish.
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Chapter 4
Immunosuppression of Adult Zebrafish
Current approaches to immunosuppress zebrafish include chemical or radiation
immunoablation (Stoletov & Klemke, 2008). Dexamethasone is the chemical standard
used for immuonsuppresion in zebrafish prior to cell implantation (Langenau et al., 2004;
Patton et al., 2005; Stoletov et al., 2007). The typical concentration for 30 day old fish is
10 µg/ml of water (Stoletov et al., 2007). However, in order to ensure there is a sufficient
amount of tumor tissue for in depth RNA and histological analysis, significantly larger
individuals will be needed around, 3-6 month old fish, for these experiments. Based on
this premise, we wanted to assess three different concentrations of dexamethasone
(10µg/ml, 15µg/ml and 20µg/ml) to identify Maximum Tolerated Dose (MTD) for 3-6
month old fish.

However, dexamethasone treatments can result in unwanted morbidity

and mortality, reducing the efficiency of the experimental system (Ignatius & Langenau,
2009). Therefore we wanted to see if in fact dexamethasone is needed in order for
successful engraftment to occur. An additional experiment was conducted to determine if
dexamethasone treatment is necessary for tumor growth in the host fish.
Methods
Maximum tolerated dose of dexamethasone experiment. A total of fifteen, 3-6
month old AB fish were used for these experiments (3 groups of 5). The fish were
housed in breeder tanks (Carolina) at 1 Liter of water per tank.

Three different

concentrations of dexamethasone (Sigma; 10mg, 15 mg, and 20 mg) was dissolved in 1
ml of DMSO and added every day to the corresponding group for 10 days. The fish
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were closely monitored for stress (such as rapid gill movement, failure to eat, and
lethargy).
Determining if dexamethasone immunosuppression is necessary for engraftment.
A total of ten fish were anesthetized, and IP implanted with 2x105 GBMERBB2-RFP
cells (exactly as mentioned in chapter 5) . The treated group (n=5 fish) was given 15
µg/ml of dexamethasone each day. The control group was given DMSO without
dexamethasone. The fish were then xenogen imaged on day 2 and day 9 for presence or
absence of cells based on RFP.
Results and Discussion
Maximum tolerated dose identified. One of the caveats of xenograft models, is that
in order to prevent rejection the host immune response must be prevented (Sachs, Winn,
& Russell, 1971; Schroeder & DiPersio, 2011) In mice this is achieved by using
immunodeficent/immunoablated strains (Belizário, 2009) Unfortunately, such
immunocompromised fish aren’t currently available, so the fish immune system must be
suppressed either chemically or through radiation (Langenau et al., 2004; Traver et al.,
2004). Dexamethasone is commonly used in fish (Langenau et al., 2004; Patton et al.,
2005; Stoletov et al., 2007). In order to determine what concentration would be effective
in 3-6 moth old fish, we tested 3 different concentrations. The group that was exposed to
20 µg/ml of dexamethasone exhibited severe bleeding from the mouth at day 3 and were
immediately euthanized. However, no aberrant effects were visible for the other 2 groups
until day 14, when individuals from both groups exhibited similar bleeding as the 20
µg/ml group. Based on the fact there was no marked difference between the 10 and 15
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µg/ml groups, the 15 µg/ml concentration of dexamethasone was used for the subsequent
experiments.
Dexamethasone is necessary for tumor growth in adult zebrafish. Because
dexamethasone is a harsh immunosuppressant and is used in combination with or by
itself as a chemotherapy, we wanted to assess if was necessary to administer for tumor
growth (Gertz et al., 1995; Ito et al., 1996; Peterson et al., 1996). By day 9, there
was no detectable fluorescence (RFP) in the untreated group, however, in the treated
group RFP was still robust indicating that dexamethasone immunosuppression is
necessary for tumor engraftment to occur (Figure 6).

Figure 6. Dexamethasone is required for engraftment of tumor cells.
RFP was present in dexamethasone treated fish at day 9 compared to the
control fish in which RFP in absent.
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Chapter 5
Identifying optimum anatomical sites for implantation of tumor cells
There are three main concerns when assessing the best anatomic location for cell
implantation: 1) the survival of both the host and implanted cells, 2) clinically relevant
microenviroment, and 3) visibility of the
implanted cells. Two anatomical areas
were initially assessed for implantation
(intramuscular (i.m), and intraperitoneal
(i.p.), in order to first gain experience in
handling zebrafish before ultimately
attempting intracranial injections. Then

Figure 7. Anatomical areas used for
implantation of mammalian tumor cells. Four
different anatomical areas were used in order to
optimize cell engraftment while maintaining
fish survival. (a) Intramuscular (b).
Intraperitoneal (c) Intracranial (d). Intranasal

intracranial (i.c) injections were attempted using 2 different sites for implantation.
Methods
Preparing cells for implantations. Glioblastoma cells (GBMERBB2-RFP) were
cultured as previous described in Chapter 2. The tumorspheres were transferred into a 15
ml conical tube (Corning®) and spun at 40 × g for 5 minutes to separate media from the
spheres. The media was aspirated using glass pipette and the tumorspheres were
dissociated in 2 mls of Stempro® Accutase ® for 15 minutes. Tumorspheres were then
mechanically dissociated using a p1000 pipette and Fresh Neurobasal® medium (Gibco)
was then added to the dissociated cells a final volume of 10 mls. The cell suspension was
spun at 4000 × g for 5 minutes to pellet the cells and the Accutase/media was aspirated
leaving the pellet. The cells were then re-suspended in 1 ml of neuralbasal media and 20
µl of cell suspension was added to 20 µl of 0.02% trypan blue in a 1.5 ml eppendorf.
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The cells were counted using a Cellometer® (Nexcelom). Dissociated cells were
prepared in cell suspension (1 x 106 cells/5µl of neural basal media) based on the cell
density used in mouse xenograft implants (Atkinson et al., 2011).
Fish preparation. Sixty two fish were anesthetized using 0.04% (40ml) tricaine in a
100 mm cell culture dish (Corning®) and placed on a 100 mm cell culture dish lid.
Using a stereomicroscope on brightfield setting (2x magnification), fish were gently held
using forefinger and thumb then injected with 1 ul of cell suspension (2 x 105 cells) using
30 gauge Hamilton syringe (n= 25 fish were i.m. injected, n=12 were i.p. injected n=15
fish intracranial through supraoccipital crest, and n=10 fish were intracranial injected
through intranasal cavity) . Implanted fish were placed into clean breeder tank with 1
liter of fish water containing 15 µg/ml of dexamethasone, where they were monitored for
signs of post implantation stress (bleeding, rapid respiration based on gill movement or
erratic swimming) , and immediately euthanized.
Results and Discussion
Injection of GBMERBB2-RFP cells into the intraperitoneal cavity and
intracranial-intranasal of the adult zebrafish resulted in lowest mortality. Out of the
25 fish that were i.m injected with cells, only 5 lived 24 hours after injection (Figure 7a).
Additionally, the surviving fish exhibited the inability to swim and were subsequently
euthanized. Unlike the i.m. injected fish, the i.p. injected cohort exhibited low mortality
(8 of 12 survived; Figure 7b). For the intracranial injections, the first area tested was the
area just below the supraoccipital crest (Figure 7c) and the second injection site was
intranasal (Figure 7d). None of the 15 fish survived the supraoccipital crest injections
and were all dead by day 2. However, eight of the ten fish survived intranasal
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implantation and lived for 20 days and then were subsequently euthanized. Although
both the i.p. and intracranial-intranasal injected fish exhibited low mortality, the
intracranial injected rout provided a means for developing a clinically relevant orthotopic
zebrafish model. This would allow for the targeting of tumor cells in a more clinically
relevant microenvironment. Additionally, it has been demonstrated that metastasis not
only is more efficient in orthotopic models, but it reflects the human disease more closely
than non-orthotopic models (Konantz et al., 2012)
Tumors failed to develop after i.c or i.p implantation. Unfortunately, despite
identifying ideal anatomical candidates for implantation sites based on fish survival, none
of the 27 individuals that were either i.c or i.p implanted with cells produced tumors.
Fluorescence stereomicroscopy readily detected similar amounts of RFP+ cells in all
zebrafish for up to 24 hours following implantation; but no tumor cells were detectable in
recipient zebrafish three days after implantation by fluorescence stereomicroscopy. In
order to validate what was observed using stereomicroscopy, three individuals from each
anatomical implantation group was processed for histological examination (see chapter 2
for histological processing). Individuals were serial sectioned using paraffin microtomy,
at 5 µm per section, 4 sections per slide, and every 5th slide was H and E stained, and
closely examined for presence of tumor using up-right bright field microscopy, 200 ×
magnification (TS100 Nikon). Two independent observers examined the tissue, and
after close histological examination, no tumors were observed.
Possible reasons for failure of tumor growth. There are three main reasons for
failed tumor development: 1) immunosuppresion wasn’t adequate enough allowing
immune system clearing of the tumor, 2) the fish host environment is insufficient
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(lacking appropriate cytokines) for mammal cell survival and growth, and/or 3)
temperature range between species prevents tumor growth . Although reason 1 and 2 are
likely, based on our results, increasing dexamethasone concentration to further suppress
the fish immune system would likely end in high mortality of the fish. Although it is
possible that fish lack important cytokines for mammal tumor cell growth, literature
supports that fish xenografts are possible (Konantz et al., 2012), and there is conservation
of genes between species (Barbazuk et al., 2000) There is evidence that temperature
differences effects tumor growth and that conditioning fish at higher temperature resulted
in successful xenograft tumor development (D. W. Jung et al., 2012).
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Chapter 6
Temperature conditioning of cells and fish
As mentioned in chapter 5, it was reasoned that the marked difference in body
temperature between mice (37oC) and zebrafish (~28oC) might account for the failed
engraftment of tumors (D. W. Jung et al., 2012). To test this hypothesis, we first
conditioned freshly isolated cultures of mouse GBMERBB2-RFP to grow at 35oC by
reducing the temperature of cultured cells by 0.75oC per week for 4 weeks. Similarly,
we acclimatized 14 zebrafish to an ambient temperature of 35oC by increasing their water
temperature by 1oC per day for six days (Pruvot et al., 2011).
Methods
Conditioning of tumor cell lines and fish. Mouse brain tumor cells (GBMERBB2RFP , EPRTBD-RFP , CPCRFP, EPEPHB2-RFP and control NSCRFP) were harvested
from mice and cultured under conditions that promote neural stem cell growth (see
chapter2). The temperature of the tumor cell cultures were reduced by 0.75°C per week
for 4 weeks. Forty, three month old wild-type (AB) or Fli1:GFP transgenic zebrafish
were acclimatized to an ambient temperature of 34oC by increasing tank water
temperature by 1°C per day for six days using an aquarium heater. The fish were then
implanted intracranialy with 2x105, 10 fish per tumor cell type using injection methods
established in chapter 5. Implanted fish were placed into clean breeder tank with 1 liter
of fish water containing 15 µg/ml of dexamethasone, and imaged using fluorescence
stereomicroscopy on days 1, 3, and 5 (Figure 7).
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Results and Discussion
Remarkably, under these conditions, all four tumor cell types demonstrated robust
and rapid engraftment in zebrafish brains, resulting in death of recipient fish within a
median of five to seven days (Figure 8a and b). Serial IFM of zebrafish readily detected
reproducible and significant increases in fluorescence, indicative of tumor growth
(EPRTBDN-RFP, p=0.001; EPEPHB2-RFP, p=0.008; GBMERBB2-RFP, p=0.002, CPCRFP, p=0.02;
Mann-Whitney Figure 8). In contrast, no fish harboring NSCRFP cells displayed
increased fluorescence or tumor development.
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Figure 8. Generation of orthotopic mouse brain tumor xenografts in
zebrafish. (a) Mouse brain tumor cells were harvested from mice and
cultured under conditions that promote neural stem cell growth (ref.
7). (b) The temperature of brain tumor cultures was reduced by
0.75oC per week for 4 weeks. (c) Zebrafish were acclimatized to an
ambient temperature of 35oC by increasing their water temperature by
1oC per day for six days. (d) 2x105 of each tumor cell type were
injected using an 30 gauge syringe via the nostril into the brains of
zebrafish. (e) Zebrafish were subject to intravital fluorescence
microscopy to monitor tumor growth. .
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Figure 9. Fluorescently labeled cell lines from four different pediatric
brain tumors enable direct observation of tumor growth. (a,b,c) The
implanted fluorescently labeled cells can easily be tracked in anesthetized
fish using fluorescent stereomicroscopy. (d) A Kaplan-Meier curve
illustrating that the majority of fish died of tumor burden between days 5
and 6 while the fish harboring control cells exhibited 100% tumor free
surivival. (e) A total of thirty two adult wildtype AB fish, 8 fish per tumor
cell line, were anesthetized using 0.04% tricaine and imaged using
fluorescence stereomicroscopy at day one, three and five post implantation.
Graphs represent relative fluorescence of the three days measured for each
tumor type. Values represent mean + s.e.m., *P < 0.05, **P<0.01. The
mean intensity of fluorescence was measured using NIS Elements version
3.2. Statistical analysis was conducted using a two-tailed Mann-Whitney
test using GraphPad Prism version 6.
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Chapter 7
Testing Fidelity of Models
It is crucial that xenograft models maintain fidelity of the parent tumor in order to be
useful for preclinical drug screening (D. Lin et al., 2014; Zhao et al., 2012). As an initial
test of the fidelity of our brain tumor xenografts, we reviewed the histology and
immunophenotype of all tumors (Figure 9). Then molecular fidelity was also assessed.
Methods
Histological processing and analysis. Zebrafish harboring tumors were euthanized
using 0.04% tricaine and fixed in 4% paraformaldehyde overnight. Zebrafish were then
decalcified using 0.5M EDTA (AMRESCO®) for 5 days, rinsed in phosphate buffered
saline, dehydrated and paraffin wax embedded. 5µm sections were stained using
hematoxylin and eosin (H&E) or subjected to standard immunohistochemistry using the
indicated primary antibodies (GFAP 1:500, Dako rabbit polyclonal Z0334; ERBB2 1:40,
Vector mouse monoclonal VP-C380; Ki67, 1:1000, Vector rabbit polyclonal vp-K451).
TTR expression was visualized by in situ hybridization using a full length TTR cRNA
template (BC032069, generous gift of Dr. Edwin Monuki). Paraffin sections were treated
with RNAzip (Ambion, Austin, TX) and de-waxed to water. Probe hybridization was
performed at 600C overnight in standard hybridization buffer. Sections of the same
tumors growing in mouse brains were analyzed in parallel for comparison. Arrows in
EPRTBDN-RFP H&E and GFAP mark pseudorosettes and GFAP+ tumor cells respectively.
Fli1:GFP zebrafish harboring tumors were euthanized fixed and decalcified as described
above. Brains containing tumor were then cryo-protected in 30% sucrose for 2 days and
frozen in tissue freezing media (TBS®). 12µm sections were counter stained using DAPI
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containing hard set mounting media and imaged by confocal microscopy with 488nm and
594nm filters.
Collection of tissue for RNA analysis. Total RNA was extracted from flash frozen
tumor samples from both mouse derived tumor samples (CPC = 57, ependymoma EphB
2 = 8, glioblastoma = 7) and tumors derived in fish (CPC =8, ependymoma RTBDN =
10, ependymoma EphB2 = 6, glioblastoma = 22). Expression profiles were generated
using 430v2 arrays as well as the Peg array. Unsupervised hierarchical clusters were
constructed using Spotfire® software. To compare the expression profiles of mouse and
fish derived tumors the Agreement of Differential Expression (AGDEX) was used
(Johnson et al., 2010a).
Results and Discussion
Hematoxylin and eosin stains (see methods chapter 2) confirmed that each mouse
brain tumor retained its hallmark morphological features when xenografted into zebrafish
brains: EPRTBDN-RFP and EPEPHB2-RFP tumors in both mouse and zebrafish contained
pseudorosettes and were glial fibrillary acidic protein (GFAP) immunoreactive;
GBMERBB2-RFP tumors in both species displayed cellular pleomorphism, had high mitotic
rates (indicated by robust Ki67 nuclear immunoreactivity), and were intensely ERBB2
and GFAP immunoreactive; and CPCRFP tumors displayed a typical epithelioid
morphology and expressed transthyretin receptor (Ttr) that is highly restricted to normal
and malignant choroid plexus (Herbert, Cavallaro, & Dwork, 1990) (Figure 10).
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Figure 10. Mouse brain tumors retain key biologic characteristics when xenografted into
zebrafish brains. (a) Histological comparisons of mouse and fish tumors. Arrows in EPRTBDNRFP
H&E and GFAP mark pseudorosettes and GFAP+ tumor cells respectively. Dotted line in
bottom right GBMERBB2-RFP H&E demarcates tumor invading normal brain. Arrow indicates
mitotic tumor cells. (b) The recruitment of host vasculature by GBM and ependymoma when
implanted into the Fli1:GFP zebrafish harboring tumors . (c) Arrows in H&E of EPRTBDN-RFP
tumors mark individual metastatic deposits.
Brain tumors have a propensity to disseminate through the central nervous system
(Kramm et al., 1996). Therefore, to test if zebrafish xenografts also metastasize, we
generated cohorts of zebrafish implanted with EPRTBDN-RFP, GBMERBB2-RFP, or CPCRFP
cells and monitored the spines of each animal using daily fluorescence stereomicroscopy
(Figure 10b). 5.3% (5/94), 11.1% (n=3/27), and 23.1% (n=3/13) of zebrafish bearing
GBMERBB2-RFP, CPCRFP, and EPRTBDN-RFP tumors, respectively, developed RFP+ masses
along the spinal axis that were distinct from the main implanted tumor. In each case
spinal masses were undetectable immediately following cell implantation but developed
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one to two days post implantation. Histologic analyses of the complete CNS of each
animal confirmed that these masses were independent, distant, deposits of tumor rather
than direct extensions of the main tumor mass (Figure 10c). Thus, implanted mouse
brain tumors disseminate through the CNS of zebrafish and IFM of these tumors may
serve as a useful tool for studying brain tumor metastasis in vivo.
Mouse Gliomas Retain the Transcriptome of Their Parent Tumor in Zebrafish.
To test more comprehensively if our xenografts recapitulate the biology of the
corresponding parent mouse brain tumor, we used Affymetrix M430 microarrays to
compare the transcriptomes of GBMERBB2-RFP, EPRTBDN-RFP, and CPCRFP tumors growing
in both species. Unsupervised, hierarchical clustering of tumor transcriptomes confirmed
that, regardless of host species, samples of the same tumor type are related to each other,
but are distinct from other tumors (Figure 11). To test if the transcriptome of any given
tumor type grown in mice correlates with the transcriptome of the same tumor type
grown in zebrafish, we used our recently developed AGDEX algorithm that estimates the
degree of similarity between transcriptomes derived from different tissues (Johnson et al.,
2010; Pounds et al., 2011a). A positive AGDEX score indicates a positive correlation in
transcriptome between compared tissues; the significance of this correlation is assigned a
permuted p-value that controls for false discovery. All three tumor types displayed
positive AGDEX scores, indicating that the mouse and zebrafish brain tumor
transcriptomes are positively related (Figure 11). GBMERBB2-RFP correlated particularly
closely with the parent mouse tumor suggesting that zebrafish xenografts of this tumor
are especially faithful reproductions of the parent tumor (AGDEX score 0.24, permuted
p=0.02; Figure 11).
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Figure 11. Zebrafish brain tumors maintain genotypic fidelity.
Total RNA was extracted from the indicated brain tumors grown in
mouse and zebrafish brains. Microarray gene expression profiles
were generated using Affymetrix 430v2 arrays and subject to
unsupervised hierarchical clustering exactly as described (Johnson et
al., 2010). Transcriptomes of each tumor type grown in mouse and
zebrafish brains were directly compared using the Agreement of
Differential Expression (AGDEX) algorithm exactly as described
was used(Johnson et al., 2010).
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Chapter 8
Testing Drugs against Fish Xenografts
Since GBMERBB2-RFP xenografts most closely recapitulated the histology and
transcriptome of their parent mouse tumors, we used this model to test our system as a
preclinical drug development tool. Current cancer chemotherapies can be broadly
divided into non-specific cytotoxic drugs and small molecule inhibitors of specific
tumorigenic proteins ((Lombardo et al., 2004; Zhang, Yang, & Gray, 2009). We selected
one drug each from these two classes that have known activity against human GBM: the
cytotoxic antimetabolite 5-fluorouracil (5-FU) (Walbert et al., 2011) and tyrosine kinase
inhibitor, Erlotinib (Prados et al., 2006) that targets ERBB2 that is mutated in human
GBM (TCGA, 2008) and drives GBMERBB2-RFP.
Methods
In vitro drug tests. For in vitro drug screening, we used methods established by
Atkinson et al 2011. 750 GBM Cells were seeded in 100 µl of neurobasal medium in
each well of 96-well plates (Corning) using an automated plate filler (Wellmate, Matrix).
For the drug plate, alternating rows of 5 FU (starting concentration: 20 mM) and erlotinib
(starting concentration: 6.9 mM) were diluted at a 1:3 ratio. The plate also contained
cycloheximide, which was used for the positive control (50mM) as well as DMSO for the
negative control. After 24 hrs, 142 nl of solution containing the compounds were pin
transferred into the 96-well plates resulting in final concentrations of: 5FU Highest 28.4
µM to lowest 14.4x10-3µM, erlotinib: highest 9.6 µM to lowest 4.9 x10-4. After 72 hour
incubation, cell number was determined in each well using the Cell Titer Glo reagent

49

(Promega) and read in an automated Envision plate reader (Perkin-Elmer). Dose
response curves were constructed using GraphPad Prism 6.
Testing drugs in fish. A total of 19 adult zebrafish were implanted orthotopically
with GBMERBB2-RFP cells. All fish were then imaged using fluorescent intravital
microscopy 24 hours after implantation. The dose of erlotinib per fish was determined
based on the dose given to mouse (100 mg/kg). (128) Therefore, the average weight of 5
fish (365 mg) was used to calculate the dosage used per fish ( 0.036 mg). To test the
response of fish to erlotinib, two groups of fish were treated with two different dosages,
group one (a) was treated with 0.036 mg/ml and group two (b) was treated with 0.072
mg/ml respectively. Each fish was anesthetized using 0.01% tricaine and then orally
gavaged using a p10 pipette. For the control group, five adult fish were treated with
vehicle only 5% DMSO. On day 3, all fish were imaged again, and the fluorescence was
measured using NIS Elements version 3.2 (Nikon). Statistical analysis was conducted
using a two-tailed Mann-Whitney U test using GraphPad Prism version 6.
For the 5 FU study, the maximum tolerated dose of 4.7 mM was assessed by adding
increasing concentrations(1mM to 4.8mM) of 5-FU (APP Pharmaceuticals,LLC) to 1
liter of fish water containing 3-5 fish until reaching 100% mortality. To test the response
of 5-FU on tumor bearing fish, 12 zebrafish adults were implanted with 2 X 105
GBMERBB2-RFP. The Maximum Tolerated Dose (MTD) of 5-FU was then
administered to 7 of the 12 fish for two consecutive days while the remaining eight were
used as a control.
Histological analysis of treated tissue. Since erlotinib inhibits the ERBB2 tyrosine
kinase that drives GBMERBB2-RFP tumors, we used phospho-specific
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immunohistochemistry to test if the drug inhibited ERBB2 signaling brain tumors in
zebrafish Immunohistochemistry of active, phospho-ERBB2Y1248 receptor expression in
GBMERBB2-RFP tumors taken from fish treated with erlotinib of vehicle control.
Immunostaining was performed as described previously using ERBB2Y1248 rabbit
polyclonal antibody (Novus Biologicals NB 100-81960).
Results and Discussion
Zebrafish glioblastoma model responds to Erlotinib. First, we confirmed that
GBMERBB2-RFP are sensitive to 5-FU and Erlotinib with IC50s of 0.34µM and 0.21µM,
respectively. For this study, fish orthotopic glioblastoma models were produced as
previously described (Chapter 5). The dose of Erlotinib per fish was determined based on
the dose given to mouse (100mgs/kg). (Abraham et al., 2011) Therefore, the average
weight of 5 fish (365mg) was used to calculate the dosage used per fish (0.036mgs). To
test the fish glioma model response to Erlotinib, seven adult fish were gavaged with the
drug (0.036mg each) and five fish were treated with vehicle only (5% DMSO). Based on
fluorescence, there was not a significant difference between vehicle and treated fish
(p=0.0526; p<0.05; Figure. 1a). However, in a subsequent experiment there was a
significant difference between treated and vehicle when the dosage was doubled to 0.072
mgs per fish (p= 0.0450; p< 0.05; Figure 12).
Glioblastoma fish model also responds to 5-FU. Next, we wanted to know if this
model would respond to chemotherapeutics by testing it against 5-fluorouracil (5-FU), an
antimetabolite shown to be effective against the human GBM (Grunda et al., 2010). To
test the response of 5-FU on tumor bearing fish, 12 zebrafish adults were implanted with
glioblastoma cells. Then 5-FU (4.7mM) was administered to 7 of the 12 fish for two
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consecutive days while the remaining 5 were used as vehicle controls. All the fish were
fluorescently imaged after injection then again prior to each drug treatment. Surprisingly,
after each treatment, the fish showed a significant decrease in fluorescence (Treatment #
1 p<0.0001 and Treatment #2 p<0.0001; p < 0.001; Figure 12).
We tested two commonly used chemotherapeutics against our glioblastoma fish
model in order to test the feasibility of using zebrafish to “bridge the gap” between in
vitro and in vivo drug screening. Our results indicate that by using fish tumor models the
drug screening process could be fine-tuned, enabling promising therapeutics to enter the
clinic in a timely manner. The antimetabolite, 5-Fu is a pyrimidine analog used in the
treatment of many different types of cancer (Longley, Harkin, & Johnston, 2003). It is a
suicide inhibitor and works through irreversible inhibition of thymidylate synthase.
Erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine
kinase, which is highly expressed and occasionally mutated in various forms of cancer
(Nakamura, 2007). Both of these drugs have been shown to be efficacious against
glioblastoma. These promising results illustrate the potential and future use of zebrafish
for preclinical screening. Finally, since erlotinib inhibits the ERBB2 tyrosine kinase that
drives GBMERBB2-RFP tumors, we used phospho-specific immunohistochemistry to test if
the drug inhibited ERBB2 signaling brain tumors in zebrafish (Figure 12e). Intense,
membrane and cytoplasmic pERBB2Y1248 immunoreactivity was readily detected in
GBMERBB2-RFP cells in the brains of three independent, vehicle treated fish. In stark
contrast, pERBB2Y1248 immunoreactivity was virtually undetectable in GBMERBB2-RFP
tumors three days following the onset of erlotinib therapy (Figure 12e). Thus, erlotinib
effectively inhibits ERBB2 signaling in tumor cells in the zebrafish brain.
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Figure 12. Zebrafish brain tumor models can be used for preclinical drug testing.
(a) Dose response curve of GBMERBB2-RFP tumor cells exposed to 5-FU or (b)
Erlotinib. (c) Zebrafish harboring GBMERBB2-RFP tumors were established
exactly as described in Figure 1. After 24 hours zebrafish were treated by
addition of vehicle only or 4.7mM 5-FU to the tank water on two consecutive
days. All zebrafish were imaged exactly as described in Figure 2. (d) Graph left
reports the growth of tumors shown in (b) (fluorescence relative to day 1) in fish
treated with 5-FU or vehicle only. Graph left reports the same for zebrafish
treated with erlotinib. Erlotinib was administered at doses of 200mg/kg by oral
gavage. (e) Immunohistochemistry of active, phospho-ERBB2Y1248 receptor
expression in GBMERBB2-RFP tumors taken from fish treated with erlotinib of
vehicle control. Immunostaining was performed as described in Figure 3 using
ERBB2Y1248 rabbit polyclonal antibody (Novus Biologicals NB 100-81960).
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Chapter 9
Conclusion
We report the first orthotopic models of mouse brain tumors in adult zebrafish. All
models recapitulate the histology of their parent tumor. In addition, our glioma model
retained a similar gene expression profile to its parent tumor. We further show that
metastasis can be imaged in live zebrafish. Imaging of metastasis and other cellular
processes in mice is challenging, in large part because existing fluorescence,
bioluminescence and radiological imaging of mice has limited resolution. The
translucency, small size, and ease of husbandry of zebrafish renders them useful for
studying hematopoetic and solid malignancies in peripheral tissues in vivo (Stoletov &
Klemke, 2008; R. White, Rose, & Zon, 2013). Our demonstration that tumor
dissemination can also be visualized in the zebrafish CNS could greatly enhance
understanding of the biology and treatment of brain metastasis. This is especially
important since primary brain tumors kill patients by direct or metastatic invasion of the
nervous system (Lacy, Saadati, & Yu, 2012), and brain metastasis of peripheral solid
cancers are a major cause of morbidity and mortality (N. U. Lin et al., 2013).
Our zebrafish system also allows preclinical testing of potential new brain tumor
therapies. Tumor-bearing zebrafish embryos are an established system for the conduct of
chemical genetic and therapeutic screens of cancer (Hong, Tsang, & Dawid, 2008;
Suzanne Ridges et al., 2012; Stoletov & Klemke, 2008; R. White et al., 2013; R. M.
White et al., 2011). Indeed, drug screens against melanoma in zebrafish embryos have
led directly to human clinical trials of the dihydroorotate dehydrogenase inhibitor,
Leflunomide. Since zebrafish embryos can be maintained and treated in multi-well
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plates, they are a valuable whole organism system for conducting chemical screens (R.
M. White et al., 2011). However, the bathing of embryos in drug solution does not
accurately model clinical drug dosing and it is unclear if tumors growing in developing or
mature tissues are equivalently responsive to drugs. Our system allows for testing of
drugs against brain tumors growing in the adult brain. We further show that oral gavage
(erlotinib) or direct tank water administration (5-FU) of drug can be used to treat tumors
in this system.
We are currently working to refine our zebrafish brain tumor models. Adult zebrafish
need to be immunosuppressed to accept tumor xenografts since there are no widely
available immunodeficient mutants. Current approaches to immunosuppress zebrafish
include chemical or radiation immunoablation (Stoletov & Klemke, 2008). However,
these treatments can result in unwanted morbidity and mortality, reducing the efficiency
of the experimental system. Therefore, we are investigating whether recently described
immunodeficient but viable mutant strains e.g., Rag1-/-(Wienholds, Schulte-Merker,
Walderich, & Plasterk, 2002) can accept tumor xenografts without the need for
exogenous immunosuppression. Additional mutant strains may also improve the utility
of our model system. The relative translucency of zebrafish facilitates transcranial
fluorescence imaging of brain tumors; however, the resolution of this imaging could be
increased dramatically in mutants that lack melanophores or iridiophores e.g., Casper
mutant (R. M. White et al., 2008).
Although our models hold promise to advance the treatment of brain tumors, several
questions need to be addressed before zebrafish can be formally integrated into the drug
development pipeline for these diseases. In particular, the degree to which drug efficacy
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in zebrafish predicts activity in mice and humans remains to be determined and it will be
important to determine if differences in the pharmacokinetics of drugs in zebrafish, mice
and humans influence drug pharmacodynamics. Ongoing parallel studies of zebrafish
and mouse systems should answer these important questions.
Understanding the expression heterogeneity between the fish ependyomoma and CPC
xenografts compared to the mouse parent tumors is also important and should be
investigated further as expressional changes may have adverse effects on targeted therapy
(Giannini et al., 2005; Joo et al., 2013). There are many possibilities as to why the
changes in expression occurred: 1) Both the ependymoma and the CPC model may have
had to “reprogram” themselves in order to adjust to a foreign host environment. 2) The
treatment of dexamethasone may have affected the expression of the tumors.
Dexamethasome is an anti-inflammatory agent. Cytokines produced by inflammatory
cells may be necessary for tumor genetic maintenance (Coussens & Werb, 2001; Kulbe et
al., 2007), which is another reason why it is important to explore other mechanisms for
immunosuppresion. 3) Temperature conditioning of the ependymoma and CPC cell lines
may have affected expression 4) In order to maintain genetic fidelity, the ependymoma
and CPC models may require specific cytokines that are present in mouse
microenvironment whereas these specific cytokines maybe lacking in the zebrafish host
microenvironment.
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Future Studies
Based on that fact that the GBM zebrafish models respond to two compounds that
have shown efficacy against the disease, the next obvious step would be to screen
compounds with unknown efficacy against our tumor models in order to further test the
value of the zebrafish system. Also, not only may zebrafish be useful for screening
compounds, they may be useful in screening oncogene candidates as well. Our lab
conducted a large genome-wide analysis of the human ependymoma that identified >100
candidate oncogenes (1). However the next step, assessing the biologic function of each
of these genes in order to determine whether or not they are bona fide oncogenes, is much
more difficult to conduct in a timely manner especially using transgenic methodology
(Table 2). Recently direct orthotopic lentiviral injections have shown promise as a way
to produce de novo tumors in mice. If this system is able to be adapted using zebrafish, it
may prove to be a more cost effective method for screening potential oncogene
candidates.

Table 2.
Genes that were driven by different promoters in an attempt to develop transgenic
brain tumor models in zebrafish.

Genes and Promoter
Used
Gfap-hNICD
Gfap-HRAS

Number of Embryos
Injected
200

Number of Tumors
Produced
1

150

0

Gfap-EphB2

200

0

Blbp-ErbB2

100

0

Blbp-EphB2

100

1

Blbp-hNICD

200

0
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Figure Appendix
Figure 1. Ependymomas from different parts of the CNS are molecularly distinct
diseases.
Figure 2. 5 FU demonstrating in Vivo Efficacy against mEPEphb2
Figure 3. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and
biological subgroups of glioblastoma
Figure 4. A xenogen image taken of zebrafish implanted with RFP positive GBM cells.
Figure 5. A comparison between xenogen imaged (photons/sec) and stereomicroscope
imaged (mean intensity) tumor bearing fish.
Figure 6. Dexamethasone is required for engraftment of tumor cells.
Figure 7. Anatomical areas used for implantation of mammalian tumor cells.
Figure 8. Generation of orthotopic mouse brain tumor xenografts in zebrafish.
Figure 9. Fluorescently labeled cell lines from four different pediatric brains tumor
enable easy observation of tumor growth.
Figure 10. Mouse brain tumors retain key biologic characteristics when xenografted
into zebrafish brains.
Figure 11. Zebrafish brain tumors maintain genotypic fidelity.
Figure 12. Zebrafish brain tumor models can be used for preclinical drug testing.
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expiration date.
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